Drug
Ipilimumab and nivolumab
Ipilimumab and nivolumab is a pharmaceutical drug with 6 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
4(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
50%
Ph phase_2
1
17%
Ph phase_3
2
33%
Phase Distribution
3
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
6
all time
Status Distribution
Active(4)
Completed(1)
Other(1)
Detailed Status
Recruiting3
unknown1
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (50.0%)
Phase 21 (16.7%)
Phase 32 (33.3%)
Trials by Status
unknown117%
recruiting350%
completed117%
active_not_recruiting117%
Recent Activity
4 active trials
Showing 5 of 6
recruitingphase_1
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738
recruitingphase_1
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
NCT07075120
completedphase_3
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT04334759
active_not_recruitingphase_1
PHP and Immunotherapy in Metastasized UM
NCT04283890
recruitingphase_2
The Drug Rediscovery Protocol (DRUP Trial)
NCT02925234
Clinical Trials (6)
Showing 6 of 6 trials
NCT07563738Phase 1
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07075120Phase 1
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
NCT04334759Phase 3
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT04283890Phase 1
PHP and Immunotherapy in Metastasized UM
NCT02925234Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
NCT02460068Phase 3
A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6